Axogen, Inc. (NASDAQ:AXGN), a leader in the electromedical apparatus industry, has reported a recent transaction involving its Chief R&D Officer, Angelo Scopelianos, according to the latest SEC filings. The report indicates that Scopelianos engaged in both acquisition and disposition of company shares.
On March 16, 2024, Scopelianos acquired a total of 25,406 shares of Axogen common stock at no cost, reflecting the vesting of restricted stock units. Following these transactions, his total ownership in the company increased to 58,250 shares.
However, on March 21, 2024, Scopelianos sold a total of 6,881 shares of Axogen common stock at a price of $7.68 per share. These sales, which were conducted to cover tax withholding obligations associated with the vesting of restricted stock units, amounted to a total value of $52,846. After these sales, Scopelianos's holdings in Axogen decreased to 57,994 shares.
The reported transactions are part of the regular financial activities of corporate executives and are disclosed to the public through SEC filings. Investors often monitor these filings to gain insight into the actions of a company's insiders.
For those interested in following the trading activities of Axogen's insiders, the company's stock can be tracked on the NASDAQ exchange under the ticker symbol AXGN.
InvestingPro Insights
In light of the recent insider transactions at Axogen, Inc. (NASDAQ:AXGN), investors may be looking for additional context to understand the company's financial health and market position. According to InvestingPro, the company's market capitalization stands at $320.59 million, with a negative price-to-earnings (P/E) ratio of -14.66, reflecting market skepticism about future earnings. The negative PEG ratio of -0.56 further highlights this sentiment.
While the company's revenue growth is robust at 14.74% for the last twelve months as of Q4 2023, analysts are not expecting Axogen to be profitable this year. Additionally, the company's stock has experienced a significant decline over the past month, with a price total return of -29.0%. However, it's worth noting that there was a large price uptick over the last six months, indicating some volatility in the stock's performance with a return of 58.55% over that period.
InvestingPro Tips suggest that the stock is currently in oversold territory, as indicated by the RSI, which may be of interest to potential investors looking for entry points. Also, it's important to consider that Axogen operates with a moderate level of debt and has liquid assets that exceed short-term obligations, which could provide some financial stability.
For those considering a deeper analysis, InvestingPro offers additional tips for Axogen. For instance, two analysts have revised their earnings estimates downwards for the upcoming period, which could impact future stock performance. To explore these insights further and to access more comprehensive research, investors can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking a total of 9 InvestingPro Tips for Axogen.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.